Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 6/20 | 0.58 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.51 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | PARP1 | P09874 | 1/20 | 0.46 |
| ▸ | CTSS | P25774 | 1/20 | 0.45 |
| ▸ | CTSK | P43235 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | CCR5 | P51681 | 1/20 | 0.45 |
| ▸ | DPP4 | P27487 | 1/20 | 0.45 |
| ▸ | CHRNA10 | Q9GZZ6 | 1/20 | 0.44 |
| ▸ | CHRNA9 | Q9UGM1 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16695320 | 0.91 | NOTUM (0.71) | NOTUMFFAR2 | |
| SCHEMBL18286575 | 0.86 | KDM4E (0.54) | NOTUMFFAR2KDM4ETP53CHRM4 | |
| SCHEMBL16769738 | 0.86 | KDM4E (0.50) | NOTUMFFAR2KDM4ETP53CHRM4 | |
| SCHEMBL12582094 | 0.83 | PANK3 (0.49) | NOTUMFFAR2KDM4ETP53CHRM4 | |
| SCHEMBL23752715 | 0.82 | NOTUM (0.60) | NOTUMFFAR2KDM4ETP53CCR5 | |
| SCHEMBL22099629 | 0.82 | NOTUM (0.60) | NOTUMFFAR2KDM4ETP53CCR5 | |
| SCHEMBL16648433 | 0.82 | MAPT (0.61) | FFAR2KDM4ETP53CHRM4POLB | |
| SCHEMBL1164809 | 0.82 | CHRM4 (0.53) | NOTUMFFAR2KDM4ETP53CHRM4 | |
| SCHEMBL3487510 | 0.80 | KDM4E (0.47) | FFAR2KDM4ETP53CHRM4POLB | |
| SCHEMBL7753402 | 0.80 | FFAR4 (0.52) | FFAR2KDM4ETP53CHRM4POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114773249-B | Compounds, pharmaceutical compositions and methods for treating inflammatory diseases | 艾匹克治疗公司 | 2024-08-16 | — | — | CN | disclosed |
| US-20240174635-A1 | TLR 9 INHIBITORS | INSILICO MEDICINE IP LIMITED (HK) | 2024-05-30 | — | — | US | disclosed |
| US-11807622-B2 | TLR 9 inhibitors | INSILICO MEDICINE IP LIMITED (HK) | 2023-11-07 | — | — | US | disclosed |
| US-11807622-B2 | TLR 9 inhibitors | INSILICO MEDICINE IP LIMITED (HK) | 2023-11-07 | — | — | US | disclosed |
| US-11807622-B2 | TLR 9 inhibitors | INSILICO MEDICINE IP LIMITED (HK) | 2023-11-07 | — | — | US | disclosed |
| CN-114773249-A | Compounds, pharmaceutical compositions and methods for treating inflammatory diseases | 艾匹克治疗公司 | 2022-07-22 | — | — | CN | disclosed |
| EP-3917920-A1 | TLR INHIBITORS | Insilico Medicine IP Limited (CN) | 2021-12-08 | — | — | EP | disclosed |
| CN-113710659-A | TLR inhibitors | 英矽智能科技知识产权有限公司 | 2021-11-26 | — | — | CN | disclosed |
| US-20210253553-A1 | TLR 9 INHIBITORS | INSILICO MEDICINE IP LIMITED (HK) | 2021-08-19 | — | — | US | disclosed |
| US-20210253553-A1 | TLR 9 INHIBITORS | INSILICO MEDICINE IP LIMITED (HK) | 2021-08-19 | — | — | US | disclosed |
| EP-1660481-A1 | PIPERIDINE/CYCLOHEXANE CARBOXAMIDE DERIVATIVES FOR USE AS VANILLOID RECEPTOR MODULATORS | GLAXO GROUP LIMITED (GB) | 2006-05-31 | — | — | EP | disclosed |
| EP-1615909-A1 | PIPERAZINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISEASES | GLAXO GROUP LIMITED (GB) | 2006-01-18 | — | — | EP | disclosed |
| EP-1585517-A1 | USE OF SUBSTITUTED 2-PHENYLBENZIMIDAZOLES AS MEDICAMENTS | Boehringer Ingelheim International GmbH (DE) | 2005-10-19 | — | — | EP | disclosed |
| WO-2005016915-A1 | PIPERIDINE/CYCLOHEXANE CARBOXAMIDE DERIVATIVES FOR USE AS VANILLOID RECEPTOR MODULATORS | GLAXO GROUP LIMITED (GB) | 2005-02-24 | — | — | WO | disclosed |
| US-20050014810-A1 | Use of substituted 2 phenylbenzimidazoles as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-01-20 | — | — | US | disclosed |
| WO-2004101546-A1 | PIPERAZINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISEASES | GLAXO GROUP LIMITED (GB) | 2004-11-25 | — | — | WO | disclosed |
| WO-2004062663-A1 | USE OF SUBSTITUTED 2-PHENYLBENZIMIDAZOLES AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2004-07-29 | — | — | WO | disclosed |
| US-5442064-A | Anticoagulants, antiagglomerants | DR. KARL THOMAE GMBH (DE) | 1995-08-15 | — | — | US | disclosed |
| CN-1087904-A | Carboxylic acid derivative, the pharmaceutical composition that contains these compounds with and preparation method thereof | KRAL THOMAE GMBH (DE) | 1994-06-15 | — | — | CN | disclosed |
| EP-0592949-A2 | N-(aminocarbonyl)-piperidines/pepirazines as aggregation inhibiting agents | Dr. Karl Thomae GmbH (DE) | 1994-04-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210253553-A1 | TLR 9 INHIBITORS | TLR9, TLR1, TLR7 | NOTUM 3826/4885FFAR2 278/4885KDM4E 943/4885 |
| US-11807622-B2 | TLR 9 inhibitors | TLR9, TLR1, TLR7 | NOTUM 3826/4885FFAR2 278/4885KDM4E 943/4885 |
| US-20050014810-A1 | Use of substituted 2 phenylbenzimidazoles as medicaments | GLP1R, GIPR, GCGR | NOTUM 3388/4885FFAR2 112/4885KDM4E 2371/4885 |
| US-20240174635-A1 | TLR 9 INHIBITORS | TLR9, TLR1, TLR7 | NOTUM 3826/4885FFAR2 278/4885KDM4E 943/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.